Key Takeaways
- Record quarter, harvesting begins: Revenue of ₹538 cr and EBITDA of ₹151 cr are both all-time highs, and management declared the heavy investment years are over as all four business segments grew.
- Gross margin fell ~700 bps on mix: The decline is mechanical, not operational: API grew faster than high-margin formulations, and API raw material costs rose globally, a headwind that persists until input prices settle.
- Biologics is now a real business: Revenue grew 150% YoY to ₹65 cr, and management upgraded the segment from "asset under monetization" to a core business focus, with two biosimilars entering human studies this year.
- The pipeline is dense but mostly FY28+: Three complex launches (Enzalutamide, Abraxane, Rotigotine patch), a transdermal patch filing, and the first ADC biosimilar entering human studies all land in FY28, so near-term growth rests on API momentum and formulation ramp.
- What to watch next quarter: Whether API momentum holds as guided, any update on the 4 CDMO programs under global registration, and the pace of gross margin recovery if raw material costs ease.
The Inflection Narrative
- Investment phase declared closed: Management opened the call by stating the hardest years of investing ahead of revenue are behind the company and the years of harvesting are beginning, framing the record quarter as the start of a structural shift rather than a one-off.
- ROCE moving up: ROCE improved to 13.3% from 9% in FY25, with adjusted ROCE at 18.3%, helped by improved performance and positive operating leverage; management expects further improvement as plant capacities fill up.
- Deleveraged balance sheet: The company described itself as profitable and deleveraged, sitting on built capacity with a dense pipeline of differentiated launches ahead, implying the capex cycle has peaked and free cash flow should inflect.
- Multi-engine structure now firing: All four segments (API, CDMO, formulation, biologics) contributed to growth, reducing dependence on any single driver and supporting the harvesting thesis.
Bhutada: "I want to start not with the quarter's numbers. We will get to those, and they are the best in our history, but first I want to inform all our investors that the hardest years, the years of investing ahead of revenue, are behind us. The years of harvesting are beginning."
Gross Margin: The Mix Math
- Raw material cost ratio jumped ~7 pp: The ratio rose from 28.65% to 35.72% of sales because API sales grew strongly and API carries higher raw material costs than formulations; global API raw material prices also rose, and management expects the elevated ratio to continue until raw material prices settle.
- Formulation growth was actually faster: Formulation revenue grew over 50% YoY to ₹210 cr, and excluding licensing income the base business grew 87%, but API's 24% growth to ₹255 cr was enough to shift the mix meaningfully because API carries lower gross margins than formulations.
- No operational alarm: Management attributed the entire decline to mix and input costs, not to pricing pressure or operational inefficiency, and reiterated focus on high gross margin businesses like peptides, oncology APIs and CDMO going forward.
Segment Performance
| Segment | Trend | Commentary |
|---|---|---|
| API | ▲ 24% YoY | Non-captive revenue hit ₹255 cr, driven by improved uptake from newly expanded capacities and steady specialty CDMO performance; oncology grew slightly slower than non-oncology. |
| Formulations | ▲ >50% YoY | Revenue reached ₹210 cr; base business grew 87% ex-licensing, led by complex finished dosage forms in the EU, supported by U.S. and RoW. India grew 2.5x in H1 YoY, led by Nor-UDCA. |
| Biologics | ▲ 150% YoY | Revenue hit ₹65 cr on continued licensing, partnership and CDMO momentum; only Adalimumab is currently commercially supplied, so the base is still narrow. |
| CDMO (carve-out) | ▲ Steady | A dedicated CDMO platform was carved out from the API business; 4 of 25-plus NCE programs are under registration, with at least one expected to commercialize next year and three the subsequent year. |
- Europe was the standout region: Europe sales were the highest this quarter, driven by Nilotinib, Axitinib and other products; Rotigotine has not launched yet, so the base did not include that contribution.
- Nilotinib competition contained: Some generic players have entered, but the product is tender-based with 1–3 year spans, so no material near-term revenue disruption is expected.
The Pipeline: Loaded, But Mostly FY28+
- Three complex launches on track for FY28: Enzalutamide, Abraxane and the Rotigotine transdermal patch are all slated for FY28; Rotigotine was delayed by a couple of quarters due to a raw material variation approval with the European agency.
- Transdermal patch filing also FY28: Exhibit batches were completed this quarter for a complex patch product already partnered for Europe, with filing planned in FY28.
- Biosimilars entering the clinic: Two biosimilars will enter human studies for Europe and RoW markets in FY27, targeting molecules with global sales over USD 1,000 crore each; the first ADC biosimilar enters human studies in FY28.
- Nivolumab filing next year: The biosimilar is planned for filing in Europe next year, marking the company's first biosimilar for export markets.
- Recombinant human Albumin advancing: Global Phase III protocol was approved by CDSCO and EMA; IMPD submission in Europe is targeted for H2 FY27, but management called the excipient opportunity very long-term, with revenue visibility expected maybe sometime in FY28.
- NBE programs entering Phase I: Both partnership programs (Alveolus Bio and mAb Tree Biologics) will enter Phase I human studies in FY27, and Phase I supplies for three CDMO biologics client programs will be completed in the same year.
- Unicycive NDA filed: The partner filed with one additional site and received a revised PDUFA date of March 2027.
- 505(b)(2) pipeline: Five-plus complex 505(b)(2) products are in advanced development, to be commercialized in the next 2–3 years.
Bhutada: "Shilpa is not built to compete on price alone. We are built to compete on difficulty and on the complexity of the molecule."
Biologics: From Investment to Business
- Segment reclassified as core: Management stated biologics is now a real business focus and no longer an asset under monetization, reflecting the 150% YoY growth and deal momentum.
- Revenue mix is lumpy by design: Every quarter will see a mix of CDMO revenue, biosimilar revenue and licensing income; only Adalimumab is currently in commercial supply, so the revenue base will broaden as more products launch.
- Aflibercept entering India in FY27: The biosimilar will launch in the India market this fiscal year, adding a second commercial product alongside Adalimumab.
- Out-licensing pipeline: Management sees strong opportunity to out-license all seven active biosimilars in global markets in the years ahead, though no specific deals were announced.
- Dharwad plant ready: The biologics facility is approved and the fermentation unit is audit-ready, positioned for product launches as required.
Bhutada: "Biologics is now a real business focus and no longer an asset under monetization."
Capacity & Competitive Positioning
- Peptide capacity build-out underway: Two additional manufacturing lines are being added to the existing four, with space kept for further expansion; management aims to build one of the largest peptide manufacturing capacities in India, to be commissioned by end of FY27.
- Visibility still limited: Management has customer indications and confidence on volume requirements for some programs, but declined to share an order book or project count, saying more visibility will be appropriate in H2 next year.
- Investment is phased: Further peptide investments are contingent on partner uptake and utilization of the current investment; no fixed commitment beyond the current phase.
- One-stop-shop moat: Management argued the integrated model (KSM to final API in small molecules, amino acids to final peptide API, clone development to fill-finish in biologics, and in-house payload-linker-antibody-conjugation for ADCs) creates high odds of winning programs each year because partners get a single integrated solution.
- Oncology generics engine: The company is on track to complete more than 15 new oncology generic products in FY27.
- Jadcherla EU cleared, U.S. on contract manufacturing: The plant was reinspected and cleared by EU authorities; the U.S. strategy remains to manufacture products at contract sites while working with the FDA on remediation, with management stating there is zero risk to current revenue.
Dalal: "there is 0 risk to the revenue that we currently have."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| API momentum | Confident of continuing API momentum | Upcoming quarters |
| CDMO commercialization | At least 1 of 4 late-stage programs under registration to commercialize | Next year; 3 in the subsequent year |
| Oncology generic completions | More than 15 new oncology generic products | FY27 |
| Peptide capacity | One of the largest integrated peptide capacities commissioned | End of FY27 |
| Biosimilars entering human studies | 2 biosimilars for Europe and RoW | FY27 |
| NBE Phase I entry | Both partnership programs (Alveolus Bio, mAb Tree) | FY27 |
| CDMO biologics Phase I supplies | Supplies for 3 client programs completed | FY27 |
| Recombinant human Albumin IMPD | Submission in Europe | H2 FY27 |
| Nivolumab biosimilar filing | File in Europe | Next year |
| Enzalutamide, Abraxane, Rotigotine launch | Three complex product launches | FY28 |
| Transdermal patch filing | File in Europe | FY28 |
| First ADC biosimilar | Enter human studies | FY28 |
| Ondansetron launch | Launch pending state approvals | H1 FY28 |
| 505(b)(2) commercialization | 5-plus complex products | Next 2–3 years |
| ROCE | Expect further improvement with better mix and operating leverage | Coming quarters |
Key Metrics
| Metric | Q2 FY27 |
|---|---|
| Revenue | ₹538 cr, highest ever quarterly revenue, +35% YoY |
| H1 FY27 revenue | ₹1,007 cr, first time half-yearly revenues crossed ₹1,000 cr mark, +44% YoY |
| EBITDA | ₹151 cr, highest ever quarterly EBITDA, +37% YoY |
| EBITDA margin | 28% |
| H1 FY27 EBITDA | ₹290 cr, +40% YoY, margin of 29% |
| Operating PBT (before JV/associate profit and exceptionals) | ₹104 cr |
| H1 FY27 operating PBT | ₹202 cr |
| PAT | ₹79 cr |
| H1 FY27 PAT | ₹180 cr, nearly 100% growth vs H1 FY26 |
| Gross margin decline | ~700 bps sequentially and YoY (per an analyst's math), driven by higher API sales mix |
| Raw material cost to sales ratio | 35.72%, up from 28.65% in Q2 FY26 |
| Non-captive API revenue | ₹255 cr, +24% YoY |
| Formulation revenue | ₹210 cr, +50% YoY |
| Formulation base business growth (ex-licensing) | +87% YoY |
| Biologics revenue | ₹65 cr, +150% YoY |
| Biologics revenue share | 12% of total revenue |
| India business H1 growth | 2.5x YoY |
| H1 FY27 capex | ₹252 cr, funded by internal accruals |
| Net debt | ₹612 cr, stable despite increased capex |
| ROCE | 13.3%, up from 9% in FY25; adjusted ROCE 18.3% |
| NCE CDMO client programs | 25-plus, of which 4 partners' programs expected to commercialize in next 18–24 months |
| CDMO late-stage programs | 4 under registration, 2 in Phase III; at least 1 expected to commercialize next year, 3 in subsequent year |
| Biologics CDMO active programs | 6-plus; Phase I supplies for 3 programs to be completed in FY27 |
| Biosimilars portfolio | 7 molecules, average global sales of more than USD 1,000 cr each |
| Peptide manufacturing lines | 4 currently, adding 2 more; one of the largest integrated peptide capacities in India to commission by end of FY27 |
| Peptide investment announced | USD 50 million, phased |